Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for Braftovi-Erbitux-chemo.

Pfizer Inc. announced statistically significant and clinically meaningful survival results from the phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed ...

Johanna Bendell, chief oncology development officer at Pfizer, said: “The Braftovi combination helped significantly reduce the risk of disease progression or death, potentially altering the course of ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

Pfizer (NYSE:PFE) said on Friday that a late-stage trial evaluating a Braftovi combination increased survival time for patients with metastatic colorectal cancer with a BRAF V600E mutation. In the ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of the ...

Patients who received the Pfizer drug Braftovi alongside standard of care colorectal cancer therapies had a 51% lower risk of dying than patients treated with the standard of care chemotherapy.

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ...